Blood Test Might Spot Women in Labor at Risk for Preeclampsia
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
MONDAY, Oct. 21, 2024 -- A routine blood test can identify women in labor who are at risk for preeclampsia, a high-blood pressure condition that’s a leading cause of maternal death, a new study finds.
Doctors can predict a woman’s risk of developing preeclampsia by looking at her levels of two blood proteins -- fibrinogen and albumin -- when she enters the hospital for delivery, researchers reported Saturday at the American Society of Anesthesiologists’ annual meeting in Philadelphia.
Women with an elevated fibrinogen-to-albumin ratio (FAR) could have as much as a 41% increased risk of preeclampsia, researchers said.
“Our study shows that FAR can be a predictive tool that gives anesthesiologists and obstetricians a new method for assessing a laboring mom’s risk of developing preeclampsia when they are admitted to the hospital,” said lead researcher Lucy Shang, a medical student at the Icahn School of Medicine at Mount Sinai in New York City.
Between 5% and 10% of pregnant women develop preeclampsia, researchers said in background notes.
Complications can include premature birth, bleeding problems, kidney and liver damage, seizures or stroke. In severe cases, the lives of both mother and child are at risk.
Fibrinogen is involved in blood clotting and inflammation, while albumin helps maintain fluid balance and carries hormones, vitamins and enzymes throughout the body, researchers said.
Both proteins can be disrupted by preeclampsia, which can cause fibrinogen levels to rise and albumin levels to fall.
Higher FAR levels often are associated with increased inflammation, infection or serious health concerns, researchers said. The higher the FAR, the greater the concern.
For this study, researchers analyzed records for more than 2,600 women who gave birth between 2018 and 2024, including 584 with mild preeclampsia and 226 with severe preeclampsia.
Severe preeclampsia included blood pressure of 160/110 or higher and signs of organ damage, including severe headaches, elevated liver enzymes, visual disturbances, low platelet count or kidney impairment, researchers said.
There is no universally established normal value for FAR, which can range from 0.05 to 1 or higher, the researchers noted.
In this case, women with a FAR of at least 0.1 had a 24% increased risk of preeclampsia, results show. Those with a FAR of above 0.3 had an increased preeclampsia risk of more than 41%.
Doctors can take extra precautions for women at risk of preeclampsia, researchers noted -- checking blood pressure more frequently, keeping fluid levels stable and placing an early epidural for pain management.
Shang said this ratio should be assessed for all pregnant women, especially those belonging to groups at increased risk for preeclampsia, including Black women, women with high blood pressure and obese women.
Black women are 60% more likely to develop preeclampsia than white women, and are more likely to die or have serious outcomes like kidney damage, researchers said.
“Additional research is needed to determine the exact range of the FAR that would be considered concerning and would be helpful to incorporate into routine prenatal care as a predictive tool for early identification of preeclampsia,” Shang said in a meeting news release.
Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-22 00:00
Read more
- FDA Approves Cobenfy for Adults With Schizophrenia
- Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
- Prevalence of High Total Cholesterol 11.3 Percent in U.S. Adults
- Bloated After That Holiday Meal? What's Normal, What's Not
- Lack of Insurance Could Mean Later Cancer Diagnoses for Black, Hispanic Americans
- Medication Abortion Before Confirmed Intrauterine Pregnancy Noninferior
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions